
    
      The objective of this study was to asses the safety and efficacy of FK506E (MR4) as a
      long-term treatment in transplant recipients. Only patients who had participated in one of
      the phase II PK or phase III studies on FK506E (MR4) and had received at least one dose of
      study medication were enrolled.
    
  